INSULIN GLARGINE AND LIXISENATIDE (Soliqua 100/33) Nursing Considerations

What is the generic name?

INSULIN GLARGINE AND LIXISENATIDE

What is the Trade Name for INSULIN GLARGINE AND LIXISENATIDE?

Soliqua 100/33

What are the Indications for INSULIN GLARGINE AND LIXISENATIDE?

• 1 INDICATIONS AND USAGE SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. SOLIQUA 100/33 is a combination of a long-acting human insulin analog with a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use ( 1 ) : Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. Not recommended for use in combination with any other product containing a GLP-1 receptor agonist. Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Not recommended for use in patients with gastroparesis. Has not been studied in combination with prandial insulin. Limitations of Use : SOLIQUA 100/33 has not been studied in patients with a history of pancreatitis [see Warnings and Precautions (5.2) ] . Consider other antidiabetic therapies in patients with a history of pancreatitis. SOLIQUA 100/33 is not recommended for use in combination with any other product containing a GLP-1 receptor agonist [see Warnings and Precautions (5.5) ] . SOLIQUA 100/33 is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. SOLIQUA 100/33 has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis. SOLIQUA 100/33 has not been studied in combination with prandial insulin.

References: https://open.fda.gov/